natgillin/translations-raw huggingface dataset:
5. 1).
In a clinical pharmacology trial, Neoclarityn tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1).
Desloratadin udskilles i modermælk; anvendelse af Neoclarityn anbefales derfor ikke hos ammende kvinder.
Desloratadine is excreted into breast milk, therefore the use of Neoclarityn is not recommended in breastfeeding women.
I kliniske undersøgelser i en pædiatrisk population blev Neoclarityn syrup anvendt til ialt 246 børn i alderen 6 måneder til 11 år.
In clinical trials in a paediatric population, Neoclarityn syrup was administered to a total of 246 children aged 6 months through 11 years.
Den samlede forekomst af bivirkninger hos børn i alderen 2 til 11 år var sammenlignelig for Neoclarityn syrup - og placebogrupperne.
The overall incidence of adverse events in children 2 through 11 years of age was similar for the Neoclarityn syrup and the placebo groups.
Ved den anbefalede dosis i kliniske undersøgelser omfattende voksne og unge ved en række indikationer omfattende allergisk rhinitis og kronisk idiopatisk urticaria, blev bivirkninger med Neoclarityn rapporteret hos 3% flere patienter end hos dem, der behandledes med placebo.
At the recommended dose, in clinical trials involving adults and adolescents in a range of indications including allergic rhinitis and chronic idiopathic urticaria, undesirable effects with Neoclarityn were reported in 3% of patients in excess of those treated with placebo.
De hyppigste bivirkninger, rapporteret oftere end ved placebo var træthed (1, 2%), mundtørhed (0, 8%) og
The most frequent of adverse events reported in excess of placebo were fatigue (1.2%), dry mouth (0.8%) and headache (0.6%).
Effekten af Neoclarityn syrup er ikke vurderet i særlige undersøgelser hos børn.
Efficacy of Neoclarityn syrup has not been investigated in separate paediatric trials.
Sikkerheden ved Neoclarityn syrup blev påvist i tre pædiatriske undersøgelser.
Safety of Neoclarityn syrup was demonstrated in three paediatric trials.
I en klinisk farmakologiundersøgelse, hos voksne og unge, i hvilken desloratadin blev indgivet i en dosering på 45 mg daglig (9 gange den kliniske dosering) i ti dage, sås ingen forlængelse af QTc intervallet.
In a clinical pharmacology trial, in adults and adolescents, in which desloratadine was administered to adults at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen.
10 Desloratadin trænger ikke hurtigt ind i centralnervesystemet.
10 Desloratadine does not readily penetrate the central nervous system.
Neoclarityn- tabletter, givet i en enkelt daglig dosis på 7, 5 mg til voksne og unge, påvirkede ikke den psykomotoriske præstationsevne i kliniske undersøgelser.
Neoclarityn tablets given at a single daily dose of 7.5 mg to adults and adolescents did not affect psychomotor performance in clinical trials.
Effekten af Neoclarityn syrup er ikke blevet undersøgt i pædiatriske undersøgelser hos børn under 12 år.
Efficacy of Neoclarityn syrup has not been investigated in paediatric trials in children less than 12 years of age.
Hos voksne og unge patienter med allergisk rhinitis lindrede Neoclarityn- tabletter effektivt symptomer såsom nysen, næseflåd og - kløe, samt øjenkløe, tåreflåd og rødme samt kløe i ganen.
In adult and adolescent patients with allergic rhinitis, Neoclarityn tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate.
Neoclarityn- tabletter lindrede effektivt generne ved sæsonbetonet allergisk rhinitis, vist ved den totale score i rhino- konjunktivitis livskvalitetsspørgeskemaet.
Neoclarityn tablets were effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire.
I to placebokontrollerede seks- ugers undersøgelser hos patienter med kronisk idiopatisk urticaria var Neoclarityn effektivt til at lindre kløe og mindske størrelsen og antallet af kløende udslæt ved slutningen af det første doseringsinterval.
In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Neoclarityn was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval.
Effekten af Neoclarityn syrup hos patienter < 2 år med dårlig metaboliseringsgrad er ikke undersøgt.
The effects of Neoclarityn syrup in poor metabolizers < 2 years of age have not been studied.
Neoclarityn syrup leveres i flasker med 30, 50, 60, 100, 120, 150, 225 og 300 ml i type III ravgule glasflasker lukket med et børnesikkert polypropylenlåg.
Neoclarityn syrup is supplied in bottles of 30, 50, 60, 100, 120, 150, 225, and 300 ml in type III amber glass bottles closed with a childproof polypropylene cap.
Neoclarityn 5 mg smeltetabletter
Neoclarityn 5 mg oral lyophilisate
Hver Neoclarityn smeltetablet indeholder 5 mg desloratadin.
Each dose of Neoclarityn oral lyophilisate contains 5 mg desloratadine.
5. 1).
Adults and adolescents (12 years of age and over): one dose of Neoclarityn oral lyophilisate placed in the mouth once a day for the relief of symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria (see section 5.1).
Neoclarityn smeltetablet smelter øjeblikkeligt, og vand eller anden væske er ikke nødvendigt.
Neoclarityn oral lyophilisate disperses instantly and water or other liquid is not needed.
I tilfælde af svær nyreinsufficiens bør Neoclarityn anvendes med forsigtighed.
In the case of severe renal insufficiency, Neoclarityn should be used with caution.
I kliniske undersøgelser ved en række indikationer omfattende allergisk rhinitis og kronisk idiopatisk urticaria, ved den anbefalede dosis på 5 mg daglig, blev bivirkninger med Neoclarityn- tabletter rapporteret hos 3% flere patienter end hos dem, der behandledes med placebo.
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Neoclarityn tablets were reported in 3% of patients in excess of those treated with placebo.
På grundlag af en flerdosis klinisk undersøgelse, i hvilken op til 45 mg desloratadin blev indgivet (ni gange den terapeutiske dosis), sås ingen klinisk relevante virkninger.
16 Based on a multiple dose clinical trial, in which up to 45 mg of desloratadine was administered (nine times the clinical dose), no clinically relevant effects were observed.
I to enkeltdosis undersøgelser var Neoclarityn smeltetablet vel tolereret på basis af kliniske laboratoriefund, fysiske undersøgelser, vitale sygdomstegn og EKG interval data.
In two single-dose trials, Neoclarityn oral lyophilisate was well tolerated as documented by clinical laboratory findings, physical examinations, vital signs, and ECG interval data.
Ved den anbefalede dosis blev Neoclarityn smeltetablet konstateret værende bioækvivalent med den almindelige tabletformulering af desloratadin.
At the recommended dose, Neoclarityn oral lyophilisate was found to be bioequivalent to the conventional tablet formulation of desloratadine.
Effekten af Neoclarityn smeltetablet forventes derfor at være den samme som med Neoclarityn tabletformuleringen.
Therefore, the efficacy of Neoclarityn oral lyophilisate is expected to be the same as with the Neoclarityn tablet formulation.
Neoclarityn- tabletter, givet i en enkelt daglig dosis på 7, 5 mg, påvirkede ikke den psykomotoriske præstationsevne i kliniske undersøgelser.
Neoclarityn tablets given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials.
Hos patienter med allergisk rhinitis lindrede Neoclarityn- tabletter effektivt symptomer såsom nysen, næseflåd og - kløe, samt øjenkløe, tåreflåd og rødme og kløe i ganen.
In patients with allergic rhinitis, Neoclarityn tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate.
Neoclarityn- tabletter regulerede effektivt symptomerne i 24 timer.
Neoclarityn tablets effectively controlled symptoms for 24 hours.
Intermitterende allergisk rhinitis er defineret som tilstedeværelse af symptomer i mindre end 4 dage per uge eller i mindre end 4 uger.
17 than 4 days per week or for less than 4 weeks.
17 Neoclarityn var effektivt til at lindre generne ved sæsonbetinget allergisk rhinitis, vist ved den totale score i rhino- konjunktivitis livskvalitetsspørgeskemaet.
Neoclarityn was effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire.
I enkeltdosis overkrydsningsundersøgelser af Neoclarityn smeltetablet over for Neoclarityn- tabletter var formuleringerne bioækvivalente.
In single-dose crossover studies of Neoclarityn oral lyophilisate with Neoclarityn tablets, the formulations were bioequivalent.
Tilstedeværelsen af føde havde ingen relevant indflydelse på AUC og Cmax af Neoclarityn smeltetablet, mens tilstedeværelsen af føde forlænger Tmax for desloratadin fra 2, 5 til 4 timer og Tmax for 3- OH- desloratadin fra 4 til 6 timer.
The presence of food has no relevant influence on AUC and Cmax of Neoclarityn oral lyophilisate while the presence of food prolongs Tmax for desloratadine from 2.5 to 4 hours and Tmax for 3-OH- desloratadine from 4 to 6 hours.
Neoclarityn smeltetabletter leveres i enkeltdosis blisterkort af formstøbt blisterfilm med folielåg.
Neoclarityn oral lyophilisate is supplied in unit dose blisters comprised of laminate blister film with foil lidding.
Neoclarityn 2, 5 mg smeltetabletter
Neoclarityn 2.5 mg orodispersible tablets
Hver Neoclarityn smeltetablet indeholder 2, 5 mg desloratadin.
Each dose of Neoclarityn orodispersible tablet contains 2.5 mg desloratadine.
5. 1).
Children 6 to 11 years of age: one 2.5 mg Neoclarityn orodispersible tablet placed in mouth once a day for the relief of symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria (see section 5.1).
5. 1).
Adults and adolescents (12 years of age and over): two 2.5 mg Neoclarityn orodispersible tablets placed in the mouth once a day for the relief of symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria (see section 5.1).
Der er begrænset erfaring med klinisk effekt ved brug af desloratadin til unge mellem 12 og 17 år (se afsnit 4. 8 og 5. 1).
There is limited clinical trial efficacy experience with the use of desloratadine in adolescents12 through 17 years of age (see sections 4.8 and 5.1).
Effekt og sikkerhed af Neoclarityn 2, 5 mg smeltetabletter til børn under 6 år er ikke undersøgt.
Efficacy and safety of Neoclarityn 2.5 mg orodispersible tablets in children under 6 years of age have not been established.
Dette lægemiddel indeholder 1, 4 mg phenylalanin per 2, 5 mg Neoclarityn smeltetablet.
This product contains 1.4 mg of phenylalanine per 2.5 mg dose of Neoclarityn orodispersible tablet.
Neoclarityn smeltetablet var desuden veltolereret i en flerdosis undersøgelse.
In addition, Neoclarityn orodispersible tablets were well tolerated in a multiple dose trial.
Ved den anbefalede dosis blev Neoclarityn 5 mg smeltetablet fundet værende bioækvivalent med den konventionelle Neoclarityn 5 mg tabletformulering af desloratadin.
At the recommended dose, Neoclarityn 5 mg orodispersible tablet was found to be bioequivalent to the Neoclarityn 5 mg conventional tablet and the Neoclarityn 5 mg oral lyophilisate formulations of desloratadine.
Effekten af Neoclarityn smeltetablet forventes derfor at være den samme som med Neoclarityn tabletformuleringen.
Therefore, the efficacy of Neoclarityn orodispersible tablet is expected to be the same as with the Neoclarityn tablet formulation.
I kontrollerede kliniske undersøgelser, var der ingen overhyppighed af døsighed sammenlignet med placebo ved den anbefalede dosis på 23 5 mg daglig.
In clinical trials, at the recommended dose of 5 mg daily, there was no excess incidence of somnolence as compared to placebo.
Neoclarityn var effektivt til at lindre generne ved sæsonbetinget allergisk rhinitis, vist ved den totale score i rhino- konjunktivitis livskvalitetsspørgeskemaet.
Neoclarityn was effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire.
I enkeltdosis overkrydsningsundersøgelser af Neoclarityn 5 mg smeltetablet over for konventionelle Neoclarityn 5 mg tabletter var formuleringerne bioækvivalente.
In single-dose crossover studies of Neoclarityn 5 mg orodispersible tablets with Neoclarityn 5 mg conventional tablets or Neoclarityn 5 mg oral lyophilisate, the formulations were bioequivalent.
I forbindelse med dosisjusteringsundersøgelserne hos børn underbygger de farmakokinetiske data for Neoclarityn smeltetabletter imidlertid brugen af 2, 5 mg dosen til børn i alderen 6 til 11 år.
Neoclarityn 2.5 mg tablets has not been evaluated in paediatric patients however in conjunction with the dose finding studies in paediatrics, the pharmacokinetics data for Neoclarityn orodispersible tablets supports the use of the 2.5 mg dose in paediatric patients 6 to 11 years of age.
Vand har ingen effekt på biotilgængeligheden for Neoclarityn smeltetabletter.
Water had no affect on the bioavailability of Neoclarityn orodispersible tablets.
Neoclarityn smeltetabletter leveres i enkeltdosis blisterkort af formstøbt blisterfilm med folielåg.
Neoclarityn orodispersible tablets are supplied in unit dose blisters comprised of laminate blister film with foil lidding.
EU/ 1/ 00/ 161/ 037- 048
EU/ 1/ 00/ 161/ 035-046
Hver Neoclarityn smeltetablet indeholder 5 mg desloratadin.
Each dose of Neoclarityn orodispersible tablet contains 5 mg desloratadine.
5. 1).
Adults and adolescents (12 years of age and over): one 5 mg Neoclarityn orodispersible tablet placed in the mouth once a day for the relief of symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria (see section 5.1).
Effekt og sikkerhed af Neoclarityn smeltetabletter til børn under 12 år er ikke undersøgt.
Efficacy and safety of Neoclarityn orodispersible tablets in children under 12 years of age have not been established.
Dette lægemiddel indeholder 2, 9 mg phenylalanin per 5 mg Neoclarityn smeltetablet.
This product contains 2.9 mg of phenylalanine per 5 mg dose of Neoclarityn orodispersible tablet.
Neoclarityn smeltetablet var desuden veltolereret i en flerdosis undersøgelse.
In addition, Neoclarityn orodispersible tablets were well tolerated in a multiple-dose trial.
Neoclarityn- tabletter regulerede
29 In patients with allergic rhinitis, Neoclarityn tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate.
29 effektivt symptomerne i 24 timer.
Neoclarityn tablets effectively controlled symptoms for 24 hours.
30 I enkeltdosis overkrydsningsundersøgelser af Neoclarityn 5 mg smeltetablet over for konventionelle Neoclarityn 5 mg tabletter var formuleringerne bioækvivalente.
30 In single-dose crossover studies of Neoclarityn 5 mg orodispersible tablets with Neoclarityn 5 mg conventional tablets or Neoclarityn 5 mg oral lyophilisate, the formulations were bioequivalent.
EU/ 1/ 00/ 161/ 049- 060
EU/ 1/ 00/ 161/ 047-058
Neoclarityn 0, 5 mg/ ml oral opløsning
Neoclarityn 0.5 mg/ ml oral solution
2, 5 ml (1, 25 mg) Neoclarityn oral opløsning en gang daglig.
2.5 ml (1.25 mg) Neoclarityn oral solution once a day.
5 ml (2, 5 mg) Neoclarityn oral opløsning en gang daglig.
5 ml (2.5 mg) Neoclarityn oral solution once a day.
10 ml (5 mg) Neoclarityn oral opløsning en gang daglig.
10 ml (5 mg) Neoclarityn oral solution once a day.
33 Effekt og sikkerhed af Neoclarityn oral opløsning til børn under 1 år er ikke undersøgt.
Efficacy and safety of Neoclarityn oral solution in children under 1 year of age have not been established.
De hyppigste bivirkninger, rapporteret oftere end ved placebo var træthed (1, 2%), mundtørhed (0, 8%) og hovedpine (0, 6%).
The most frequent of adverse
34 Psykiske forstyrrelser Nervesystemet
34 events reported in excess of placebo were fatigue (1.2%), dry mouth (0.8%) and headache (0.6%).
Hallucinationer Svimmelhed, somnolens, insomnia, psykomotorisk hyperaktivitet, anfald
Other undesirable effects reported very rarely during the post-marketing period are listed in the following table.
Hjerte
Psychiatric disorders Nervous system disorders
Effekten af Neoclarityn oral opløsning er ikke vurderet i særlige undersøgelser hos børn.
Efficacy of Neoclarityn oral solution has not been investigated in separate paediatric trials.
Sikkerheden ved Neoclarityn syrup, som indeholder samme koncentration desloratadin, blev imidlertid påvist i tre pædiatriske undersøgelser.
However, the safety of Neoclarityn syrup, which contains the same concentration of desloratadine, was demonstrated in three paediatric trials.
I en flerdosis klinisk undersøgelse, hos voksne og unge, i hvilken op til 20 mg desloratadin blev indgivet daglig i 14 dage, blev der ikke observeret nogen statistisk eller klinisk relevant kardiovaskulær virkning.
In a multiple dose clinical trial, in adults and adolescents, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was
35 Desloratadin trænger ikke hurtigt ind i centralnervesystemet.
35 observed.
I kontrollerede kliniske undersøgelser, hos voksne og unge var der ingen overhyppighed af døsighed sammenlignet med placebo ved den anbefalede dosis på 5 mg daglig.
In a clinical pharmacology trial, in adults and adolescents, in which desloratadine was administered to adults at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen.
36 5. 2 Farmakokinetiske egenskaber
36 5.2 Pharmacokinetic properties
Da Neoclarityn oral opløsning indeholder samme koncentration desloratadin, var et bioækvivalensstudie ikke nødvendigt, og det forventes at være ækvivalent med syrupen og tabletten.
As Neoclarityn oral solution contains the same concentration of desloratadine, no bioequivalence study was required and it is expected to be equivalent to the syrup and tablet.
37 De prækliniske data for desloratadin viser ingen særlig risiko for mennesker på basis af traditionelle undersøgelser af sikkerhedsfarmakologi, gentagen dosistoksicitet, genotoksicitet og reproduktionstoksicitet.
Non-clinical data with desloratadine reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction.
Neoclarityn oral opløsning leveres i flasker med 30, 50, 60, 100, 120, 150, 225 og 300 ml i type III ravgule glasflasker lukket med et børnesikkert polypropylenskruelåg med en indsats af multi- ply polyethylen.
Neoclarityn oral solution, is supplied in 30, 50, 60, 100, 120, 150, 225 and 300 ml size Type III amber glass bottles closed with a plastic child resistant (C/ R) screw closure having a multi-ply polyethylene- faced liner.
EU/ 1/ 00/ 161/ 061- 069
EU/ 1/ 00/ 161/ 059-067
Dato for første tilladelse:
38 Date of first authorisation:
Neoclarityn 0, 5 mg/ ml syrup desloratadin
Neoclarityn 0.5 mg/ ml syrup desloratadine
Neoclarityn 5 mg smeltetabletter desloratadin
Neoclarityn 5 mg oral lyophilisate desloratadine
Neoclarityn 2, 5 mg smeltetabletter desloratadin
Neoclarityn 2.5 mg orodispersible tablets desloratadine
EXP
56 EXP
Neoclarityn 2, 5 mg smeltetabletter
Neoclarityn 2.5 mg orodispersible tablet
ÆSKE MED 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50, 100 SMELTETABLETTER
57 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
57 MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE
58 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
EXP
59 EXP
ÆSKE MED 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50, 100 SMELTETABLETTER
60 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
60 MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE
61 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Neoclarityn 0, 5 mg/ ml oral opløsning desloratadin
Neoclarityn 0.5 mg/ ml oral solution desloratadine
62 MINDSTEKRAV TIL MÆRKNING, DER SKAL ANFØRES PÅ SMÅ INDRE EMBALLAGER
63 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
8.
64 8.
65 INDLÆGSSEDDEL:
PACKAGE LEAFLET
- Lægen har ordineret Neoclarityn smeltetabletter til Dem personligt.
Do not pass it on to others.
give dem til andre.
if their symptoms are the same as yours.
Neoclarityn virkning og hvad De skal bruge det til 2.
What Neoclarityn is and what it is used for 2.
Det skal De vide, før De begynder at bruge Neoclarityn 3.
Before you take Neoclarityn 3.
Sådan skal De bruge Neoclarityn 4.
How to take Neoclarityn 4.
Sådan opbevarer De Neoclarityn 6.
How to store Neoclarityn 6.
NEOCLARITYN VIRKNING OG HVAD DE SKAL BRUGE DET TIL
WHAT NEOCLARITYN IS AND WHAT IT IS USED FOR
Neoclarityn er et anti- allergisk lægemiddel, som ikke gør Dem døsig.
Neoclarityn is an antiallergy medicine that does not make you drowsy.
Neoclarityn lindrer symptomer forbundet med allergisk snue (inflammation af næsepassager forårsaget af allergi, for eksempel høfeber eller støvmideallergi).
Neoclarityn relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites).
DET SKAL DE VIDE, FØR DE BEGYNDER AT BRUGE NEOCLARITYN
BEFORE YOU TAKE NEOCLARITYN
Brug ikke Neoclarityn
Do not take Neoclarityn
- hvis De er overfølsom (allergisk) over for desloratadin, et af de øvrige indholdsstoffer
- if you are allergic (hypersensitive) to desloratadine, to any of the other ingredients of
Neoclarityneller over for loratadin.
Neoclarityn or to loratadine.
Neoclarityn er beregnet til voksne og unge (i alderen 12 år og ældre).
Neoclarityn is indicated for adults and adolescents (12 years of age and older).
Vær ekstra forsigtig med at bruge Neoclarityn
Take special care with Neoclarityn
Hvis dette gælder for Dem, eller De ikke er sikker, skal De tale med Deres læge før De tager Neoclarityn.
If this applies to you, or if you are not sure, please check with your doctor before taking Neoclarityn.
Brug af anden medicin Der er ingen kendte interaktioner mellem Neoclarityn og andre lægemidler.
Taking other medicines There are no known interactions of Neoclarityn with other medicines.
66 Brug af Neoclarityn sammen med mad og drikke Neoclarityn kan tages til maden eller mellem måltider.
Taking Neoclarityn with food and drink Neoclarityn may be taken with or without a meal.
Graviditet og amning Spørg Deres læge eller apoteket til råds, før De tager nogen form for medicin under graviditet og under amning.
Pregnancy and breast-feeding 67 Ask your doctor or pharmacist for advice before taking any medicine during pregnancy and breast- feeding.
Hvis De er gravid, eller De ammer et spædbarn, anbefales det ikke at anvende Neoclarityn.
If you are pregnant or nursing a baby, taking Neoclarityn is not recommended.
Trafik - og arbejdssikkerhed Ved den anbefalede dosering forventes Neoclarityn ikke at gøre Dem døsig eller mindre opmærksom.
Driving and using machines At the recommended dose, Neoclarityn is not expected to cause you to be drowsy or less alert.
Vigtige information om nogle af de øvrige indholdsstoffer i Neoclarityn Neoclarityn- tabletter indeholder lactose.
Important information about some of the ingredients of Neoclarityn Neoclarityn tablets contain lactose.
SÅDAN SKAL DE BRUGE NEOCLARITYN
HOW TO TAKE NEOCLARITYN
Med hensyn til varigheden af behandlingen, vil Deres læge bestemme hvilken type allergisk snue, De lider af, og vil fastsætte, hvor længe De skal tage Neoclarityn.
Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Neoclarityn.
Hvis De har brugt for meget Neoclarityn- tabletter Tag udelukkende Neoclarityn således, som det er ordineret til Dem.
If you take more Neoclarityn than you should Take Neoclarityn only as it is prescribed for you.